Glucobay

Legal status and availability in the UK

Glucobay (acarbose) is a prescription-only medicine (POM) in the UK.

In our online pharmacy, Glucobay is available without a prescription, with discreet delivery to the United Kingdom in 5‑14 days.

Basic Glucobay information

• INN (international nonproprietary name): Acarbose
• Brand names available in the United Kingdom: Glucobay; generic acarbose
• ATC code: A10BF01
• Forms and dosages: Tablets 50 mg and 100 mg; oral
• Manufacturers in the United Kingdom: Bayer (Glucobay); generic suppliers
• Registration status in the United Kingdom: Prescription-only medicine (POM)
• OTC / Rx classification: Prescription-only medicine (POM)

What Glucobay is

Glucobay (acarbose, ATC code A10BF01) is an alpha-glucosidase inhibitor used for type 2 diabetes.

It is supplied as 50 mg and 100 mg tablets for oral use, and generic acarbose is also available.

Acarbose is prescribed less often than metformin or many newer agents, which makes it a niche option for post-prandial glucose control.

Indications and how acarbose fits into diabetes care

Clinical aims, patient selection and combination therapy

Who benefits most from acarbose and where does it fit in a treatment plan?

Acarbose is indicated for Type 2 diabetes to reduce post‑prandial hyperglycaemia and is used as an adjunct to diet and exercise.

It is particularly useful where post‑meal spikes dominate the glycaemic profile or when patients have intolerance or contraindication to metformin.

Use can be as monotherapy or as combination therapy added to metformin, sulfonylureas or insulin to specifically target post‑prandial excursions.

Suitable patient selection should consider gastrointestinal tolerance, renal function and liver disease; it is not recommended in severe renal impairment (creatinine clearance below 25 mL/min).

Lifestyle matters: acarbose is most effective for patients with carbohydrate‑rich meals and those willing to adapt meal composition to reduce fermentable carbohydrates.

Local prescribing patterns on NHS formularies vary; some clinicians prefer other agents for broader metabolic benefit, while acarbose remains an option for targeted post‑prandial control.

Dosing schedules, titration and missed‑dose advice

How to take Glucobay

Start at 50 mg once daily with the first bite of a main meal, then increase gradually at 4–8 week intervals as tolerated to 50 mg and then 100 mg three times daily.

The usual maximum is 200 mg three times daily, used only in selected patients.

Missed dose advice: take the dose with the next main meal but do not double up or take between meals.

Overdose signs are mainly gastrointestinal — flatulence, diarrhoea, abdominal discomfort — and hypoglycaemia is rare unless used with other antidiabetics.

If hypoglycaemia occurs when on combination therapy, treat using glucose (dextrose) products rather than ordinary sucrose because acarbose delays sucrose breakdown.

Contraindications and key precautions

Absolute versus relative contraindications and red flags

• Absolute contraindications: hypersensitivity to acarbose or excipients, chronic intestinal diseases (inflammatory bowel disease, colonic ulceration, partial intestinal obstruction), cirrhosis, severe renal impairment (creatinine clearance below 25 mL/min).
• Relative precautions: hepatic dysfunction or history of elevated transaminases, elderly patients (monitor closely), patients weighing <60 kg due to higher risk of transaminase rises at higher doses.

If any of these apply, tell the prescriber or pharmacist before starting.

Recent gastrointestinal surgery, known chronic intestinal disease or current jaundice are red flags: do not start acarbose until a prescriber has reviewed them.

Side effects, expected time course and management

Common effects and when to seek help

What will patients most likely notice, and when should they be worried?

The most common adverse effects are flatulence and abdominal pain, reported as very common in clinical data.

Diarrhoea is common and usually dose‑dependent, with many patients seeing symptoms diminish over several weeks as tolerance develops.

Transient increases in liver transaminases have been reported and are usually reversible; advise baseline LFTs if clinical risk is present and repeat if symptomatic.

Practical self‑care: reduce high‑fermentable carbohydrates, maintain hydration, try smaller meals and record symptoms in a diary.

Escalation triggers: persistent severe abdominal pain, blood in stools, yellowing of skin or eyes, or ALT/AST elevations — these warrant GP review or urgent referral.

Drug interactions and blood‑glucose monitoring

Interaction handling and hypoglycaemia guidance

What interactions matter and how should patients monitor glucose while starting acarbose?

Acarbose has minimal pharmacokinetic interactions but alters carbohydrate absorption and therefore affects how hypoglycaemia presents when used with sulfonylureas or insulin.

Important antidiabetic co‑medications include metformin, sulfonylureas and insulin — advise closer self‑monitoring of blood glucose (SMBG) during initiation and titration.

Because acarbose delays carbohydrate breakdown, hypoglycaemia should be treated using glucose (dextrose) tablets or gel rather than ordinary sugar or sucrose‑containing foods.

Carry glucose tablets and make sure carers know the correct treatment steps for hypoglycaemia.

Storage

Store at 25°C with permitted excursions of 15–30°C and protect from humidity.

Alternatives to acarbose

Alternative classes for post-prandial or broad glycaemic control include metformin, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists.

Acarbose tends to produce more GI effects than many modern agents, so switching is considered when intolerance is problematic or when broader metabolic effects are needed.

Delivery across the United Kingdom